15 September 2021 - interim results
The AIM-listed supplier of medical instruments has announced interim results for the six months to 30 June and, as expected, these have shown a significant improvement on the comparable period in 2020 which was adversely affected by COVID-19. Revenues for the period rose by 63% over the previous year to £4.22m with the result that the adjusted operating loss fell to £0.15m from £0.87m in 2020. Net cash at the end of the period was £2.66m (31 December 2020: £3.10m). These results have benefited from a return to . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
